Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISTINE: Telmisartan vs Losartan in Hypertension with Metabolic Syndrome
NCT05843162Phase 4Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of telmisartan in essential hypertension, metabolic syndrome, sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
telmisartan
03
Conditions
essential hypertensionmetabolic syndrome
Beyond the preview
Go deeper on NCT05843162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843162.